Disease Landscape Analysis

The Doloxe’s Disease Analysis reports provide you with in-depth coverage of disease landscape by epidemiology, drugs, clinical trials, deals and companies.

REQUEST DEMO

Disease Landscape Analysis

The reports are enhanced using industry benchmark methodologies to provide data, analysis, and insights across well-established countries. Highlights include:

Disease market size by condition, treatment line and estimated approved drugs.
Algorithm based drug sales estimates.
Survey based analysis using KOL opinions, high-volume prescribers and payers

Benefits for Healthcare Players:

Start-up and Contract Research & Manufacturing Companies:
Monthly newsletter with drug developments and contacts keep them up-to-date with material events and business leads.
Market size projections help you to get the business scope for raising investment.
Search for planned trials with CROs as collaborator within your sales territory.
Biopharma Companies:
Informed with competitor events and execute corporate planning by keeping a track on future drug and clinical trials milestones expected from your competitors.
Customize your key events tracking based on companies in the same technology or disease or target.
Generic Drugs and API manufacturer:
Helps you to plan drug portfolio management or strategy based on key pipeline class of drugs (future market share) and disease market by country.
Support you with planned trials by disease, sponsors/collaborators.
API, & Intermediates Manufactures:
Key pipeline class of drugs (future market share); disease market by key countries.
Generics by active ingredient in US, EU, & Japan, and Patent expiry for key pipeline and marketed drugs.
Financial Firms:
Keep track on early stage biotech companies and proactively evaluate companies based on future events and clinical trial success rates.
Set alerts for material events at companies within your portfolio or competing companies that may affect the valuation of your portfolio companies.